Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD2 | Q9BYW2 | 13/20 | 0.56 |
| ▸ | NSD2 | O96028 | 4/20 | 0.51 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25040762 | 0.87 | SETD2 (0.59) | SETD2NSD2MAPTNPC1THRB | |
| SCHEMBL25039743 | 0.83 | SETD2 (0.56) | SETD2NSD2NPC1MAPK1RAB9A | |
| SCHEMBL25040666 | 0.82 | SETD2 (0.58) | SETD2NSD2MAPTNPC1THRB | |
| SCHEMBL25039829 | 0.81 | SETD2 (0.63) | SETD2NSD2MAPTNPC1THRB | |
| SCHEMBL25040178 | 0.81 | SETD2 (0.59) | SETD2NSD2MAPTNPC1THRB | |
| SCHEMBL21739856 | 0.81 | SETD2 (0.56) | SETD2NSD2KAT6A | |
| SCHEMBL25040215 | 0.81 | SETD2 (0.56) | SETD2NSD2MAPTNPC1THRB | |
| SCHEMBL25040262 | 0.81 | SETD2 (0.56) | SETD2NSD2MAPTNPC1THRB | |
| SCHEMBL26100274 | 0.81 | SETD2 (0.56) | SETD2NSD2MAPTNPC1THRB | |
| SCHEMBL25040301 | 0.80 | SETD2 (0.56) | SETD2NSD2KAT6AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | SETD2 1/4885NSD2 35/4885KAT6A 517/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | SETD2 3/4885NSD2 14/4885KAT6A 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.